Newsletter · · Ashutosh Agarwal

AbbVie Buys Apogee for 10.9 Billion as a Biotech M&A Super-Cycle Accelerates - Pharma / Biotech / Life Sciences Podcast Recap - Week of June 28, 2026

Pharma, biotech and life-sciences podcast recap for the week of June 21-28, 2026. AbbVie agreed to buy Apogee Therapeutics for $10.9 billion as a patent-cliff-driven M&A super-cycle collided with an FDA regulatory thaw, while Lilly's Mounjaro became the world's top-selling drug and the XBI hit a five-year high.

Pharma / Biotech / Life Sciences Podcast Recap

Week of June 28, 2026: AbbVie Buys Apogee for 10.9 Billion as a Biotech M&A Super-Cycle Accelerates

Coverage this week was deep and clearly investment-relevant. The dominant narrative is a Big Pharma M&A "merger mania" super-cycle colliding with an FDA regulatory thaw, set against the now-familiar GLP-1 land-grab where Lilly has decisively pulled ahead of Novo. Biotech sentiment is the most bullish it has been in years: the XBI hit a five-year high. (One caveat woven through the week: roughly a third of the relevant episodes were clinical-education ASCO recaps from physician channels rather than investor-facing shows; the investment signal is pulled out of those and flagged where investor color was thin.)

1. Dominant Themes

(A) The M&A "merger mania" super-cycle, patent cliffs are forcing the buying. AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash ($135/share, a 49% premium to Apogee's Thursday close of $90), expected to close in Q3. The prize is Apogee's lead atopic-dermatitis biologic (zumilokibart, an IL-13 asset engineered for roughly quarterly dosing versus every-2-to-4-weeks for Dupixent and Lilly's Ebglis). It is AbbVie's biggest deal since the $63B Allergan/Botox takeout in 2019. AbbVie shares rose ~7% on the announcement and ~17% on the week; Apogee jumped ~47% to $132. Founding backers Fairmount Funds and Venrock held >20% combined (Brew Markets) (BioCentury This Week) (Bloomberg Intelligence).

This sits inside a broader wave. Per BioSpace's tally: GSK/Nuvalent ~$10.6B (precision oncology, the third and largest deal under new GSK CEO Luke Miels); Lilly already ~$21B of smaller transactions by end-April; and Sun Pharma/Organon $11.75B in April (the year's largest cross-border deal). AbbVie/Apogee displaced GSK/Nuvalent as the year's second-largest and the largest in "biopharma proper." The explicit driver is loss-of-exclusivity (LOE): Humira (2023, already passed), Merck's Keytruda (2028), Sanofi's Dupixent (2031) (BioSpace).

JPMorgan's healthcare bankers framed the macro: the XBI is at a five-year high, with "record-setting pace" across converts, follow-ons and IPOs. They led the largest-ever biotech follow-on (Revolution Medicines) and largest-ever biotech IPO (Kylara) in the same week, plus the largest-ever European biotech private sell-side (Tubulus to Gilead). On China: 150 east-to-west BD deals in 2025, ~$135B of biobucks, ~$7B upfront (Making Sense).

(B) GLP-1 / obesity, Lilly's tirzepatide is now the world's #1 drug. Lilly's tirzepatide franchise generated $12.8B in Q1 2026 (Mounjaro $8.66B + Zepbound $4.16B). Mounjaro became the world's top-selling drug by quarterly sales for the first time, ending Keytruda's reign since Q1 2023. Mounjaro's ex-US sales ($4.4B) overtook US sales for the first time. Both Novo brands fell sequentially: Ozempic -$602M and Wegovy -$551M vs Q4 2025. FY2026 sell-side consensus: Mounjaro $33.1B (the new annual #1, ahead of Keytruda $30.8B); Zepbound $19.3B, taking the tirzepatide franchise >$52B; the four big GLP-1s combined ~$80B (Citeline / Scrip). A new Evaluate projection sees Mounjaro+Zepbound >$70B by 2032, plus Lilly's newly approved (April) oral weight-loss pill Famdeo at >$25B (BioSpace).

Next-gen pipeline is the forward story: retatrutide (Lilly's triple-G GLP-1/GIP/glucagon agonist) showed 28.3% mean weight loss at 80 weeks (12mg dose), with 62.5% of patients achieving ≥25% weight loss, approaching bariatric-surgery levels, though tolerability worsens at higher doses (nausea 42%, vomiting 25%) (The Obesity Guide). The drug drew headlines after Lilly granted compassionate-use access to a single well-connected 79-year-old patient, fueling speculation it was President Trump (the White House denied) and raising ethics questions about preferential access in obesity (The Readout Loud).

(C) FDA "reversal train," a regulatory thaw under new leadership. With Marty McCary and Vinay Prasad both gone and Kyle Diamantis as acting commissioner, the FDA is unwinding a string of restrictive rare-disease decisions. uniQure's AMT-130 Huntington's gene therapy (75% slowing of progression) is now cleared to submit a BLA for accelerated approval in Q3, exactly the path uniQure originally wanted before the agency demanded a sham-surgery control. Regenxbio's Hunter-syndrome gene therapy will also resubmit in Q3 with no new study required. Replimune's melanoma therapy (two prior CRLs) was re-accepted, with a decision possible in August. Sanofi's Tzield (Type 1 diabetes) and a Moderna ADCOM round out the list (BioCentury This Week) (BioSpace). BioCentury characterized this as "reversion to the mean" but flagged a worrying new pattern of political appointees (and even a White House lawyer) attending company meetings on live approval decisions. The agency is also pushing to reshore early-stage trials from China and move from two pivotal trials to one (BioCentury This Week).

(D) AI drug discovery, real partnerships, real milestones. Verge Genomics (now rebranded) detailed its $706M Lilly ALS target-discovery partnership: 83% of AI-derived targets validated in wet-lab work versus Lilly's 20% expectation, and Lilly optioned two into its internal pipeline in 2024. A parallel AstraZeneca/Alexion deal was $25-42M upfront with $700-800M total milestones (This Week in Startups). Separately, AlphaFold's John Jumper is leaving Google DeepMind for Anthropic (Alphabet fell ~5%), and NVIDIA/SandboxAQ touted physics-based virtual screening (BioNemo) (Brew Markets) (Squawk on the Street).

(E) Oncology / ASCO 2026, the RAS breakthrough headlines. Revolution Medicines' daraxonrasib (multi-selective RAS inhibitor) drew a standing ovation at ASCO: a randomized Phase 3 in previously treated metastatic pancreatic cancer showed HR ~0.4 and a doubling of median OS from 6.6 to 13.2 months, in both RAS-mutant and wild-type patients (Oncology Overdrive). Other practice-shaping ASCO data: enfortumab vedotin + pembrolizumab in bladder cancer (EV-302, 44% OS at 3.5 yrs) and trastuzumab deruxtecan (TDXD) sweeping HER2+ breast trials (ASCO Daily News) (Research To Practice).

(F) CDMO capacity & reshoring. Samsung Biologics is onshoring via a Rockville, Maryland facility (10K/20K-liter, previously used by GSK), with customers now demanding multi-node redundancy and vertical integration at launch rather than a single manufacturing site (Off Script).

(G) China biopharma. China supplied ~30% of globally licensed assets and roughly half of total partnership value in 2025, evolving from straightforward licensing toward "newco" and multidimensional strategic alliances (The BioCentury Show).

2. Active Debates

  • Lilly vs Novo on obesity, increasingly one-sided. The data now favor Lilly decisively (Mounjaro overtaking Ozempic/Wegovy, retatrutide's efficacy ceiling, oral Famdeo). Everybody's Business framed Lilly's dominance as "superior science" plus CEO Dave Ricks' political relationship with Trump (Everybody's Business). The MetSera bidding war (below) showed even Novo is now playing catch-up via M&A.
  • Is the M&A wave rewarded or punished? BMO's Evan Siegerman: "The right deals get rewarded. The wrong ones get punished... if a company buys a company for just synergies, they're going to get punished." AbbVie being rewarded with a +7% pop is seen as a self-reinforcing signal to Merck, Amgen and others to keep buying (Closing Bell).
  • Orphan/rare-disease value vs the "needle-mover" problem. The FDA thaw makes clinical-stage rare-disease assets "immediately more valuable" and many are still marked down, but Motley Fool's hosts pushed back that orphan drugs, even at high prices, aren't massive revenue generators, so blockbusters still move the needle (Motley Fool Hidden Gems).
  • Is the FDA thaw durable or temporary? BioSpace captured the rare-disease developers' "whiplash" (guidance in 2024, the opposite in 2025, and reversals again now) and asked whether the constructiveness survives the next permanent commissioner. BioCentury flagged the political-involvement risk as a reason for caution (BioSpace) (BioCentury This Week).
  • Has biotech bottomed / is the XBI inflection real? Consensus on the shows is firmly bullish: XBI five-year high, +83% over the trailing year, M&A and IPO windows wide open. The bear hedge from JPM: if inflation worsens and rate hikes get pulled forward, biotech financing markets (converts to follow-ons to IPOs to venture) could seize up (Closing Bell) (Making Sense).
  • Pharma as a group is a poor bet, pick winners, not the ETF. Motley Fool's stat: of the dozen largest global pharma companies, only three beat the S&P 500 over the past decade (a high hurdle), and even Novo Nordisk has trailed the market over 10 years as competition arrived. "I would hate to buy an ETF for this industry and just track it" (Motley Fool Hidden Gems).
  • GLP-1 trial integrity / commoditization. A growing headache: placebo-arm patients in obesity trials are dropping out or self-sourcing commercial GLP-1s (16% of Boehringer's Synchronize-1 placebo arm; 34% placebo dropout in a Roche Phase 2), muddying late-stage readouts for the chasing pack (Citeline / Scrip). MetSera's CEO argued the counter-thesis, that differentiation (a true monthly injectable) still wins in a crowded market (Running Through Walls).

3. Stock-by-Stock Bull / Bear

Eli Lilly (LLY). Bull: Widely called the best-run big pharma; tirzepatide patents run to 2036 (one of the most favorable LOE profiles in the group); world's #1 drug; oral Famdeo launching; retatrutide and amylin combos extend the franchise; disciplined bolt-on M&A; up ~7% on the day with Q2 enthusiasm around the oral launch. Bear: Tirzepatide is >half of revenue (concentration); Brazil compulsory-licensing risk on Mounjaro/Zepbound; messaging tension between "obesity is a chronic disease" and a push into consumer/aesthetics (e.g., a $100M-led investment into hair-loss biotech AbSci) (Citeline / Scrip) (Motley Fool Hidden Gems) (The Readout Loud). Lilly is also a stalking-horse bidder for Sangamo assets in its bankruptcy auction (BioSpace).

Novo Nordisk (NVO). Bull: BMO said Novo "sounds really good heading into the quarter, potentially a guidance upgrade," with the oral Wegovy ramp ahead (Closing Bell). Bear: Ozempic and Wegovy both declined sequentially in Q1; Mounjaro overtook them; Novo lost the MetSera bidding war to Pfizer despite a rare topping bid; has trailed the market over a decade as the GLP-1 monopoly eroded (Citeline / Scrip) (Running Through Walls).

AbbVie (ABBV). Bull: Cash-rich with 30% operating margins; Skyrizi + Rinvoq approaching/over $50B combined ($7.3B last quarter, nearly half of revenue); Apogee adds a next-gen, convenient-dosing atopic-derm asset; the market rewarded the deal. Bear: Skyrizi faces a new oral competitor in J&J's icotrokinra (Tremfya franchise); Apogee is clinical-stage with no product revenue and an unproven asset; this is the perennial post-Humira pipeline-rebuild treadmill (Bloomberg Intelligence) (BioCentury This Week) (Closing Bell).

Merck (MRK). Bull: BMO's favored large-cap pharma; a "very credible" Keytruda LOE rebuild (smart deals, the Cidara/"Sedara" flu prophylactic, solid SAC-TMT ASCO data); seen as a likely continued acquirer. Bear: Keytruda is >half of revenue and goes off patent in 2028, a tight timeline that "leaves little room for error" (Closing Bell) (Motley Fool Hidden Gems).

Revolution Medicines (RVMD). Bull: Daraxonrasib's pancreatic Phase 3 (HR ~0.4, OS doubling to 13.2 months) is a genuine breakthrough in an "undruggable"/"graveyard" indication; broad RAS franchise behind it (zoldanrasib G12D: 52% ORR, 11-month PFS at AACR; elironrasib G12C; RMC-5127 G12V); fastest-ever EAP turnaround; just completed the largest-ever biotech follow-on. Bear: Pre-approval, FDA rolling submission still in progress; valuation now embeds a lot of the readout (Oncology Overdrive) (Making Sense).

Iron (IRON). Bull: BMO's small-cap biotech favorite (<$3B market cap); bitopertin data due later this year in a rare skin/blood disorder with potential approval next year; additional shots in myelofibrosis and PV. Bear: Already received a CRL on a prior pathway; "up-and-down" stock (Closing Bell).

Ascendis Pharma (ASND). Bull: TransCon "time-release" conjugation platform turns burdensome daily injections into weekly/longer dosing; endocrinology base, building an oncology platform; flagged as an attractive M&A target given the platform value (Motley Fool Hidden Gems).

United Therapeutics (UTHR). Bull: Founder-led (Martine Rothblatt), six FDA-approved treatments and a robust pipeline; has "easily beaten the market" in recent years (Motley Fool Hidden Gems).

Pfizer (PFE). Context: Won the MetSera bidding war (a differentiated ultra-long-acting/monthly GLP-1, Meta-097, with an 18–19-day half-life) to address its 2029–2030 revenue gap; described as still cash-generative with low leverage despite a halved share price since the pandemic peak (Running Through Walls) (Bloomberg Intelligence).

Sanofi (SNY) / Regeneron (REGN). Bear/watch: Dupixent's 2031 LOE is the strategic clock; Apogee's asset is positioned as a direct future competitor. Sanofi also replaced its R&D chief (Houman Ashrafian out, Paulo Fontoura in from September) amid recent R&D disappointments (BioSpace) (BioCentury This Week).

GSK. Context: Nuvalent (~$10.6B, precision oncology) is the third and largest deal under CEO Luke Miels (BioSpace).

Also flagged: Boehringer Ingelheim (servidutide, 16.6% weight loss but ~20% tolerability dropout, submission in question); Roche (oral Zofluza/baloxavir generic approved; CT388 GLP-1/GIP); J&J (oral icotrokinra in psoriasis); Bristol-Myers Squibb (Eliquis, with European exclusivity lost in May and US in 2028) (Citeline / Scrip).

4. Notable Quotes

  • On AbbVie's strength: "Most pharma companies right now, if I look through the list, I can't pick one that is having trouble generating cash... these guys have 30% operating margins. So these are very cash-rich companies and the cash speaks volumes.", per Sam Fazeli, Bloomberg Intelligence senior pharmaceuticals analyst (Bloomberg Intelligence)
  • On M&A discipline: "The right deals get rewarded. The wrong ones get punished. If a company buys a company for just synergies, they're going to get punished.", per Evan Siegerman, BMO head of healthcare research (Closing Bell)
  • On the FDA reversals: "The way I look at it is kind of reversion to the mean. It's putting things back on the track that they would have been on and that they were on before Marty McCary and Vinay Prasad took over FDA.", per Steve Usdin, BioCentury (BioCentury This Week)
  • On rare-disease whiplash: "They're getting one piece of advice or guidance from the FDA in 2024. They get completely something else last year, and then they're getting basically whiplash right now... is this just under the FDA in its caretaker mode under Kyle Diamantis, or is this going to stick?", per Annalee Armstrong, BioSpace (BioSpace)
  • On the obesity differentiation thesis: "If you're going to introduce a product into a market where you already have five, ten million people with active prescriptions... you need a reason for consumers to want that drug and physicians to want to prescribe it. It can't just be another similar drug.", per Whit Bernard, CEO of MetSera (acquired by Pfizer after a bidding war with Novo) (Running Through Walls)
  • On the AI-drug-discovery thesis shift: "Instead of just buying a lottery ticket and developing a drug ourselves, can we actually make a better machine that sells those lottery tickets?", per CEO of Verge Genomics, on validating 83% of AI-derived targets for Lilly vs a 20% expectation (This Week in Startups)
  • On the RAS breakthrough: "We saw a hazard ratio of roughly 0.4, which is pretty much unheard of with most solid tumors, and a doubling of the median survival going from 6.6 months to 13.2 months... there was that standing ovation.", per Dr. Alan Sandler, Chief Development Officer, Revolution Medicines (Oncology Overdrive)
  • On LOE-driven dealmaking: "Every single large-cap pharma is staring at a different set of LOEs... they need to fill all of these LOEs, so the cycle continues. You've seen a number of large-cap pharmas almost do a deal every week now.", per Jerry Lee, global co-head of healthcare investment banking, J.P. Morgan (Making Sense)

5. Catalysts to Watch

  • Q2 pharma earnings (imminent): Lilly (oral Famdeo launch color); Novo (possible guidance upgrade per BMO) (Closing Bell).
  • Replimune FDA melanoma decision, possible ~August 2026 under expedited review (Closing Bell).
  • uniQure (Huntington's AMT-130) and Regenxbio (Hunter syndrome), BLA submissions in Q3 (BioCentury This Week) (BioSpace).
  • Revolution Medicines (daraxonrasib), FDA rolling submission ongoing under a priority-review voucher (Oncology Overdrive).
  • Medicare GLP-1 "Bridge Program" launches July 1, 2026, $50/month patient copay (government pays ~$254/month), reaching tens of millions of Medicare patients previously denied coverage; BMI-threshold eligibility, excludes diabetes/sleep apnea/MASH indications (On The Pen GLP-1 News) (The Dr. Francavilla Show).
  • AbbVie/Apogee and GSK/Nuvalent deals expected to close in Q3 (BioCentury This Week).
  • Sangamo bankruptcy auction, Lilly and Astellas as stalking-horse bidders; court-supervised auction of remaining assets (BioSpace).
  • Iron (IRON) bitopertin data later this year, with a possible 2027 approval (Closing Bell).
  • Permanent FDA commissioner appointment, the key swing factor for whether the regulatory thaw persists (BioCentury This Week).
  • Boehringer Ingelheim servidutide, decision on whether to file Synchronize-1 data or hold for further studies (Citeline / Scrip).

6. Coverage Gaps

  • Drug pricing / IRA Medicare negotiation: Very thin investor-specific commentary this week. The GLP-1 access content centered on the July 1 Medicare Bridge Program, not on IRA negotiation mechanics or innovation impact.
  • RFK Jr. / HHS policy: Most episodes that mentioned HHS were healthcare-system / insurance / Medicaid-work-requirement shows, not pharma-equity analysis. Policy read-through to pharma stocks was underrepresented.
  • Patent cliff / biosimilars (standalone): Discussed only within the M&A narrative; no dedicated biosimilar-erosion episode this week.
  • Medtech (ISRG, MDT, BSX, EW): No dedicated investor coverage surfaced.
  • Tools / CROs (DHR, TMO, A, IQV, ICLR, CRL): Not featured as a primary topic (CDMO commentary was Samsung Biologics-specific).
  • Generalist investor podcasts (All-In, Invest Like the Best, Acquired, Odd Lots, Business Breakdowns) did not run pharma/biotech as a primary subject this week; pharma appeared only incidentally on CNBC programming.
  • China biotech competition: One dedicated investor episode (Hengrui / BioCentury Show); otherwise covered only as deal-flow statistics within the broader M&A discussion.